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Background & Aims: Chronic hepatitis C virus (HCV) infection
can signiﬁcantly reduce health-related quality of life (QoL), but
it is not clear if reduction is associated with the infection or with
being aware of one’s infection status. Understanding the impact
of a HCV diagnosis on QoL is essential to inform decision-making
regarding screening/testing and treatment.
Methods: Using a cross-sectional design, we assessed QoL in
2898 people who inject drugs (PWID), surveyed in Scotland
during 2010 using EQ-5D. Multifactorial regression compared
self-reported QoL between PWID who were (i) chronically
HCV-infected and aware of their infected status, (ii) chronically
HCV-infected but unaware, and (iii) not chronically infected.
Results:Median time since onset of injecting was 10 years; not
chronically infected PWID were younger and had shorter inject-
ing careers than chronically infected PWID. Median EQ-5D was
highest for the not chronically infected and the chronic/unaware
groups (0.73) compared with the chronic/aware group (0.66).
After adjustment for demographic and behavioural co-factors,
QoL was signiﬁcantly reduced in chronic/aware compared with
chronic/unaware PWID (adjusted B = 0.09, p = 0.005); there
was no evidence for a difference in QoL between not chronically
infected and chronic/unaware PWID (adjusted B = 0.03,
p = 0.13).
Conclusions: Awareness of one’s chronic HCV status was associ-
ated with reduced health-related QoL, but there was no evidence
for further reduction attributable to chronic infection itself after
adjusting for important covariate differences.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
Introduction
More than 50,000 people are estimated to be infected with the
hepatitis C virus (HCV) in Scotland, of whom 90% are current/for-
mer people who inject drugs (PWID) [1]. The risk of progression
to severe liver disease in this population is many times that of the
general population [2–4]. Although previous research has shown
that PWID have lower QoL in comparison with reference popula-
tions [4], and chronic HCV infection can signiﬁcantly reduce
health-related quality of life (QoL) in PWID and clinical cohorts
[5,6], there is little evidence regarding the association between
QoL and awareness of one’s infection status in HCV-infected
PWID [4,7].
For estimation of the cost-effectiveness (CE) of HCV antiviral
therapy, models have used data on patients’ QoL pre- and post-
treatment; for those in the pre-treatment stage, QoL is inferred
from patients who have already been diagnosed and are aware
of their chronic HCV infection status [8]. CE studies use simula-
tion methods to project improvements in QoL post-treatment,
and baseline QoL assumptions are often derived from earlier
studies [8–9]. For estimation of the CE of HCV testing/screening
programmes [10], data are required documenting the change in
utility from untested to tested status, so that effects on QoL
attributable to the receipt of a positive diagnosis in both patients
selected and not selected for treatment can be incorporated in
the modelling.
To better understand the relationship between HCV infection,
awareness of one’s infected status, and perceived health-related
QoL, the current study compared QoL using EQ-5D (a standard-
ised measure of health status) in three subgroups consisting of
infected/aware, infected/unaware, and not chronic PWID in a
sample of approximately 3000 injectors, attending services pro-
viding injecting equipment in Scotland.
Materials and methods
Data source
The Needle Exchange Surveillance Initiative (NESI) is an ongoing project that aims
at measuring and monitoring the prevalence of HCV infection and injecting risk
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behaviours among PWID in Scotland. Starting in 2008/2009, a cross-sectional vol-
untary anonymous survey has been conducted to collect demographic, lifestyle,
and substance abuse data from PWID in 11 mainland Scottish health boards
(HBs) [11]. Participants were recruited by trained interviewers, from selected ser-
vices and pharmacies that provide injecting equipment, from January to Novem-
ber 2010. Services/pharmacies were selected to be broadly geographically
representative and to meet logistical constraints, namely availability of a room
where participants could be interviewed in private. Participants were recruited
from 109 pharmacies and 26 agencies (with 39 separate sites) providing a ﬁxed
site exchange, mobile or outreach service across the 11 mainland HBs; this rep-
resents more than half of all services providing injecting equipment in Scotland
[12]. People attending recruitment sites for other harm reduction services (e.g.,
methadone prescription) are also invited to participate.
Participants were eligible if they had ever injected drugs and had not taken
part in the current survey; non-active PWID (those who had not injected in the
past 6 months) were kept to a maximum of 25% in the sample. Dried blood spot
(DBS) samples are solicited and are tested anonymously for HCV antibody and
RNA, and test results were linked to the questionnaire data via a common study
number. Ethical approval for NESI was received from the West of Scotland
Research Ethics Service.
In the second sweep of the survey in 2010, the NESI questionnaire was
expanded to include the ﬁve-component EQ-5D [13,14], a standardised, generic
instrument for measuring QoL designed for self-completion; EQ-5D is acknowl-
edged as the most appropriate utility measure for this population [15]. The EQ-
5D questionnaire was administered face-to-face by a trained interviewer. The ﬁve
dimensions measured are: mobility, self-care, usual activities, pain/discomfort
and anxiety/depression. Each dimension has three response levels indicating
severity (no problems; some problems; severe problems). To derive a single sum-
mary index QoL value from the ﬁve-dimensional EQ-5D response state, valuations
derived from a UK general population sample (2997 respondents, 1993) were
applied using an established algorithm [16]. A maximum score of 1 indicates
the best possible health state.
DBS were supplied by 99.9% of 3100 respondents, and were tested for HCV
antibody and HCV RNA at the West of Scotland Specialist Virology Centre. Test-
ing used a modiﬁed protocol for the Ortho SAVe 2.0 ELISA (Ortho Diagnostics,
Amersham, with a reported sensitivity and speciﬁcity of 99% and 100%, respec-
tively [17]). Reactive samples were repeated using the same assay and a small
number of weakly reactive samples were tested further using modiﬁed proto-
cols of the recombinant immunoblot assay (RIBA). RNA was extracted from
DBS using the bioMerieux (Lyon, France) extraction protocol and a real-time
PCR assay was undertaken. Testing was initially carried out in pools of ﬁve then
positive pools were tested individually. After excluding participants who
declined to supply a DBS specimen (n = 2), or whose provided sample was inad-
equate for testing (n = 73), or for whom HCV and/or RNA status could not be
determined (n = 95), or who had incomplete age or sex information (n = 8), or
did not complete EQ-5D (n = 28), the study population consisted of 2898
ever-PWID.
Outcome and other variable deﬁnitions
The outcome variable was the EQ-5D summary index. The main determinant
of interest, HCV chronically infected status (chronic HCV/aware, chronic HCV/
unaware, not chronic HCV), was deﬁned according to HCV antibody and PCR
test results and the participant’s response to the question ‘Would you mind
telling me the result of your last [hepatitis C] test?’. Possible answers included
‘Have hep C’, ‘Cleared hep C’, and ‘Did not have hep C’. Speciﬁcally, the status
‘chronic HCV/aware’ was assigned to individuals who tested (anonymously)
HCV antibody-positive and RNA-positive and who self-reported as ‘Have hep
C’. ‘Chronic HCV/unaware’ relates to persons who tested HCV antibody-positive
and RNA-positive and self-reported as one of ‘Did not have hep C’, ‘Cleared hep
C’, ‘Awaiting result’, ‘Did not get result’, ‘Do not want to say’, ‘Don’t know’, ‘Not
tested’, or whose response was recorded as missing. ‘Not chronic HCV’ con-
sisted of all individuals who tested HCV RNA-negative. A small number of
cases who tested HCV antibody-negative/RNA-positive were excluded from
analysis.
Other data recorded in the NESI questionnaire included as covariates were
age, sex, injecting frequency in the previous 6 months (coded as non-active, less
than once per day, or P1 times/day), ever on methadone (never, currently, or in
past), ever in prison, and ever homeless (never, in past 6 months, or >6 months
ago). Reported alcohol consumption in the previous 12 months was coded as
non-drinker, moderate (>0 to 21 units/week for males; >0 to 14 units/week for
females), or high (>21 units/week males, >14 units/week females). Health board
of residence was divided into two categories: Greater Glasgow & Clyde (GGC),
and all other HBs.
Data analysis
EQ-5D index values were compared to published data from a UK reference pop-
ulation (n = 3395, 46% male, minimum age 18 years) for which QoL was valuated
using EQ-5D [18]; reference population mean QoL values and standard deviations
were weighted according to the sex and 10-year age group distribution of our
study population. Differences in EQ-5D index value between the study and refer-
ence populations were assessed using the two-sample t-test.
For comparison of demographic characteristics and behavioural data between
the three HCV status groups, the Kruskal–Wallis test was applied in the case of
continuous variables, and the v2 test was applied for dichotomous/categorical
variables.
Because the distribution of EQ-5D values was highly skewed, linear regres-
sion was deemed inappropriate and median (quantile) regression analysis was
used instead to estimate the association between EQ-5D index and HCV status,
adjusting for the aforementioned covariates. Tests of interactions between HCV
status and each of sex, alcohol use, and injecting frequency were planned a priori
and ﬁtted separately, and retention of interaction(s) in the ﬁnal model was deter-
mined if inclusion signiﬁcantly improved model ﬁt, according to Akaike’s Infor-
mation Criterion. All statistical analyses were conducted using R statistical
software [19].
Due to certain discrepancies between reported HCV status and actual RNA
status, (i) PWID who had tested HCV RNA-positive but had reported ‘Don’t have
hep C’ or ‘Cleared hep C’, and (ii) PWID who had tested HCV RNA-negative but had
responded ‘Have hep C’, sensitivity analyses were undertaken in which each of
these groups was excluded from the total study population.
Results
Demographic characteristics
Characteristics of the study population according to HCV status
are provided in Table 1. Overall, 67% (1941/2898) of respondents
were deemed recent PWID (injected within the previous
4 weeks). The median time since onset of injecting was 10 years;
11% had their injection debut within the previous two years.
Eighty-four percent of respondents indicated heroin to be the
only drug injected. The majority (90%) of respondents reported
having ever been on methadone (77% currently and 13% in the
past). PWID not chronically infected with HCV represented 62%
(1806/2898) of the sample, followed by chronic HCV/aware
(20%) and chronic HCV/unaware (18%). The not chronic HCV
group was younger on average and had shorter injecting careers
than either chronic HCV/aware or chronic HCV/unaware PWID
(Ps <0.001), and reported alcohol intake (summing moderate
and high intake categories) was greatest for the chronic HCV/una-
ware group.
Quality of life measures
The distribution of responses over each EQ-5D dimension is
shown in Fig. 1. The largest proportion of ‘severe’ responses
was observed for the dimensions anxiety/depression and pain/
discomfort. Mean EQ-5D index was signiﬁcantly lower in com-
parison with UK population norms (t = 46.9), after standardisa-
tion for the sex and age composition of our study population.
Table 2 displays the distribution of respondents according to
HCV test result and perceived HCV status, with unadjusted med-
ian EQ-5D for each cell of the table. A higher proportion (84%) of
HCV RNA-positive participants (from anonymous testing)
reported having been tested for HCV in the past compared with
those (75%) who were HCV RNA-negative; p <0.0001. However,
among those HCV RNA-positive who reported having ever been
tested, 21% (193/913) said that they did not have HCV (possible
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if they had been tested for HCV prior to acquiring, or developing,
chronic infection) and 5.5% (49/913) reported that they had
cleared HCV.
Fig. 2 compares crude outcome values for the three HCV status
groups. Median EQ-5D index value was highest for the not
chronic HCV (0.73, IQR: 0.35–0.84) and chronic/unaware (0.73,
IQR: 0.31–1.0) groups, compared with the chronic/aware group
(0.66, IQR: 0.21–0.85).
Multifactorial analyses
Results of multifactorial quantile regression analysis (considering
the median as the relevant measure of central tendency) indi-
cated that adjusting for covariates, chronic HCV/aware individu-
als had a signiﬁcantly lower QoL than chronic HCV/unaware
(median values of 0.66 and 0.73, respectively; regression coefﬁ-
cient = 0.09, p = 0.005), and that there was no signiﬁcant differ-
ence between the not chronically infected and chronic HCV/
Table 1. Characteristics of the study population (n = 2898), according to HCV status.
Study population Chronic HCV and 
aware (col%)
Chronic HCV and 
unaware (col%)
Not chronic HCV 
(col%)
p value
N (% of N) 2898 (100%) 584 (20%) 508 (18%) 1806 (62%)
Male 2091 (72.2) 439 (75.2) 379 (74.6) 1273 (70.5) 0.04
Age at interview in years, Median [IQR] 34 [29-39] 37 [31-42] 34 [30-40] 33 [29-38] <0.01
Injecting career length in years, Median [IQR] 10.2 [5.3-15.5] 13.5 [9.4-20.1] 11.2 [7.0-15.8] 8.5 [3.8-13.7] <0.01
Recent injector (injected in last 4 wk) 1941 (67.0) 381 (65.2) 343 (67.5) 1217 (67.4) 0.61
Injecting frequency (in previous 6 mo), if had injected in last 4 wk
<1 occasion/d 872 (45.1) 172 (39.1) 134 (46.5) 566 (44.9)
≥1 occasion/d 1069 (54.9) 209 (60.1) 209 (53.5) 651 (55.1) 0.05
Alcohol use (in previous 12 mo)
Non-drinker 1516 (52.3) 310 (53.1) 225 (44.3) 981 (54.3)
Moderate 678 (23.4) 96 (16.4) 127 (25.0) 455 (25.2) <0.01
High 704 (24.3) 178 (30.5) 156 (30.7) 370 (20.5) <0.01
Ever on methadone
Never 277 (9.6) 25 (4.3) 37 (7.3) 215 (11.9)
Currently 2244 (77.4) 481 (82.4) 391 (77.0) 1372 (76.0) <0.01
In past 377 (13.0) 78 (13.4) 80 (15.7) 219 (12.1) 0.21
Ever homeless
Never 867 (30.0) 150 (25.7) 127 (25.1) 590 (32.7)
Yes, >6 mo ago 1386 (47.9) 300 (51.4) 346 (48.5) 840 (46.6) <0.01
In last 6 mo 641 (22.1) 134 (22.9) 134 (26.4) 373 (20.7) <0.01
Ever in prison
Never 1114 (38.5) 137 (23.5) 147 (28.9) 830 (46.0)
Yes 1783 (61.5) 447 (76.5) 361 (71.1) 975 (54.0) <0.01
Health Board of residence
Greater Glasgow 1318 (45.5) 309 (52.9) 288 (56.7) 721 (39.9)
Other 1580 (54.5) 275 (47.1) 220 (43.3) 1085 (60.1) <0.001
Drug(s) injected within last 6 mo
Heroin only 1892 (83.5) 348 (80.2) 348 (85.9) 1196 (83.9)
Stimulants (± other drugs) 300 (13.2) 78 (18.0) 53 (13.1) 169 (11.9) <0.001
Other 73 (3.2) 8 (1.8) 4 (1.0) 61 (4.3) <0.001
IQR, interquartile range; d, day(s); wk, week(s); mo, month(s).
Self-rated alcohol use categories were deﬁned as: high (>21 units/week for males; >14 for females); moderate (>0 to 21 units/week for males and >0 to 14 units/wk for
females); non-drinker (0 units/week).
The Stimulants category consists of cocaine, crack, or amphetamines, with/without other reported drugs injected.
p-Values were determined according to either v2 or Kruskal–Wallis tests, for frequencies and real-valued variables, respectively.
Mo
bil
ity
Se
lf-c
are
Us
ua
l a
cti
vit
ies
Pa
in/
dis
co
mf
ort
An
xie
ty/
de
pre
ss
ion
Severe
Moderate
Mild
Pr
op
or
tio
n
0.0
0.2
0.4
0.6
0.8
1.0
n = 2898
Fig. 1. Distribution of responses among the study population, for each of the
ﬁve EQ-5D dimensions (n = 2898).
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unaware groups. Age, a high level of alcohol consumption (above
21 units/week for males, above 14 units/week for females), being
an active injector, ever being on methadone treatment, ever being
homeless, and residing in GGC were signiﬁcantly negatively asso-
ciated with the EQ-5D index, and male sex was signiﬁcantly pos-
itively associated with QoL (Table 3). No two-way interaction
terms met the criterion for inclusion.
Exclusion of those RNA-positive respondents who had
reported either ‘Don’t have hep C’ or ‘Cleared hep C’ from the
regression analysis did not appreciably change the pattern of
results; the adjusted regression coefﬁcient for chronic HCV/aware
was 0.08 (p = 0.006) and for not chronically infected was 0.03
(p = 0.138). Exclusion of those RNA-negative respondents who
reported that they ‘Have hep C’ (12%, 162/1348) from analysis
also did not change results; the adjusted regression coefﬁcient
for chronic HCV/aware was 0.09 (p = 0.003) and for not chroni-
cally infected was 0.03 (p = 0.177). A supplementary analysis
conducted for the subgroup of recent injectors (i.e., reporting
having injected within the previous 4 weeks, n = 1937) indicated
little difference in the association between HCV status and EQ-5D
compared with the entire cohort: the adjusted regression coefﬁ-
cient for chronic HCV/aware was 0.13 (p = 0.002) and for not
chronically infected was 0.06 (p = 0.08).
Discussion
This is the ﬁrst study to compare health-related QoL in PWID who
are chronically infected with HCV and aware, with those who are
chronically infected but unaware of their infected status, and
those who are not chronically infected. We found that those
chronically infected PWID that were aware of their serostatus
(relating to those who had been diagnosed) had a signiﬁcantly
lower EQ-5D summary index than those who were chronically
infected but unaware of their serostatus. Thus, diagnosis with
HCV appears to have had an additional diminishing effect upon
QoL, beyond any potential reduction in QoL associated with infec-
tion itself. Female sex, older age, heavy alcohol consumption,
active injecting, current treatment with methadone, and ever
being homeless were all independently associated with reduced
QoL. Residing in GGC compared with other health board areas
was associated with the largest QoL reduction, which captures
the greater relative social deprivation in this region [20]. Restrict-
ing analysis to recent PWID only (i.e., those who reported inject-
ing within the previous 4 weeks) made no difference to the
pattern of either outcome measure. Importantly, adjustment for
current age, which is itself highly correlated with length of inject-
ing career, is a proxy for the duration of chronic infection.
The effect on QoL from receiving a positive diagnosis needs to
be considered when calculating the CE of HCV testing/screening
programmes. Current CE models assume that QoL is reduced with
chronic infection [10,21]. Even amongst HCV antibody-positive
patients with no history of IDU, diagnosis has been shown to
reduce QoL [6]. In addition, treatment is not initiated on all
RNA-positives; not being selected for management and antiviral
therapy can reduce QoL [22]. Although approaches have been
developed to successfully test and diagnose PWID [23], atten-
dance at specialist clinics and rates of treatment initiation among
PWID are an issue.
For the population of PWID attending injecting equipment
provision services across Scotland, QoL was poorer than UK pop-
ulation norms, which corroborates the results of previous studies
[4,6,24]. Based on a cross-sectional study of 833 patients in the
Swiss Hepatitis C Cohort Study, Helbling et al. argue that this
reduction may be due to other differences with the reference
population rather than HCV per se [25]. However, in a systematic
review of studies comparing QoL (using the SF-36 instrument) in
HCV patients to matched controls, Spiegel et al. reported QoL to
be consistently and clinically signiﬁcantly lower in patients
who were HCV antibody-positive, and that the impact of HCV
Table 2. Cross-tabulation of study population (n = 2898) according to HCV test result and self-reported ever-tested and HCV status, with corresponding summary
EQ-5D values.
Anonymous HCV test result Self-reported HCV status
Have 
Hepatitis C 
Cleared
Hepatitis C
Don’t have 
Hepatitis C
Other Never tested All
Antibody+/RNA+
N 584 49 193 87 179 1092
Median index EQ-5D 0.66 0.73 0.74 0.74 0.73 0.69
RNA–
N 162 241 829 116 458 1806
Median index EQ-5D 0.63 0.73 0.76 0.74 0.78 0.73
‘Other’ includes the responses ‘Awaiting result’, ‘Did not get result’, ‘Don’t know’, and missing data.
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Fig. 2. Smoothed density plot of unadjusted EQ-5D quality of life measure-
ments according to chronic HCV infection/awareness status.
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infection was most pronounced on the vitality, general health,
physical function, and social function subscales of SF-36 [5].
Our principle ﬁnding was a reduction in QoL between HCV-
infected PWID who were aware of their infected status compared
with those who were unaware of their status. Reduced QoL in
aware compared with unaware chronically HCV-infected individ-
uals may be an effect of labelling and/or of receiving a positive
diagnosis. Awareness of (or belief about) positive HCV status in
infected individuals was associated with lower QoL in two previ-
ous studies [4,7]. In the ﬁrst, HCV-infected PWID who were
(n = 15) and were not (n = 17) aware of their serostatus were
compared in a retrospective Australian study; using the SF-36
questionnaire, the authors found that ‘aware’ PWID had a lower
QoL, 26 years after being infected [7]. In the second study, the
authors compared QoL (via SF-36) in uninfected (n = 97) and
chronically HCV-infected (n = 102) PWID in Oslo, Norway, and
found no difference between the two groups [4]. However, in
the HCV-positive group those PWID that were aware of their
infected status scored lower in 4 of 8 dimensions compared with
those who were unaware. Compared with the previous studies
reviewed above, our study population is much larger and
involved PWID recruited in community-based settings in phar-
macies and harm reductions services across Scotland.
We observed no evidence for a difference in QoL between
PWID who were not chronically infected and chronic HCV/una-
ware PWID after adjusting for important covariate differences.
This key result of our study, which had more statistical power
than most previous studies, is consistent with ﬁndings of no dif-
ference in overall QoL between HCV-infected and uninfected
groups [25–27]. For instance, comparing patients with and with-
out viraemia, Helbling et al. found that QoL did not differ between
Ab+ve, RNA+ve (n = 555) and Ab+ve, RNAve (n = 262) HCV-
infected persons [25]. In a USA study of 619 PWID, 51% of whom
were HCV antibody-positive, Costenbader et al. found that HCV
infection was associated with a signiﬁcantly reduced QoL on only
3 of the 8 SF-36 subscales [28]. Such comparisons should be made
cautiously, however, as PWID populations differ from clinical
populations in a number of respects, such as the presence of
co-morbidities and the time since infection. In the absence of
developing liver disease, HCV infection may not be sufﬁcient to
affect QoL. Given that the injecting career length of our study
population was on average only 10 years (corresponding to a
maximum of 10 years of disease progression), and in the context
that chronic HCV infection can take decades to progress to com-
plications (5–15% develop cirrhosis after 20 years of infection
[29]), it is perhaps unsurprising that our adjusted analysis found
no difference in QoL between chronic HCV/unaware and not
chronically infected PWID. Further research on QoL in those with
longer injecting careers is required.
Our results must be interpreted in the context of several
potential limitations regarding the recruitment of the study pop-
ulation and in the determination/quantiﬁcation of QoL. First, we
have assumed that willingness to participate in all aspects of
the NESI survey did not differ across HCV status groups. However,
if QoL differences between respondents and non-respondents
were not distributed equally across the three HCV status groups,
then our results may not be representative of the PWID popula-
tion as a whole.
Table 3. Results of multifactorial quantile regression analysis, where the outcome is EQ-5D index value. Analysis additionally excluded individuals with missing data
on any of: ever on methadone (n = 0), ever homeless (n = 4), ever imprisoned (n = 4); leaving 2894 cases for analysis.
Covariate Level Median (IQR) Unadjusted 
coefficient
p value Adjusted SE p value
Intercept 1.21 0.052 <0.001
HCV status RNA– 0.73 (0.35-0.85) 0.00 1.0 -0.03 0.022 0.134
Ab+/RNA+/unaware 0.73 (0.31-1.00) - - -
Ab+/RNA+/aware 0.66 (0.21-0.85) -0.07 0.018 -0.09 0.030 0.005
Sex Female 0.69 (0.29-0.85) - - -
Male 0.73 (0.29-0.85) 0.04 0.066 0.07 0.020 <0.001
Age (linear, per decade) -0.09 <0.001 -0.08 0.012 <0.001
Alcohol use Non-drinker 0.73 (0.29-0.85) - - - - -
Moderate 0.80 (0.41-1.00) 0.07 0.001 0.03 0.015 0.098
High 0.66 (0.21-0.85) -0.07 0.030 -0.07 0.030 0.012
Injecting frequency Non-active injector 0.73 (0.29-0.85) - - - - -
<1/d 0.73 (0.29-0.85) 0.00 1.0 -0.06 0.018 0.001
≥1/d 0.73 (0.29-0.85) 0.00 1.0 -0.08 0.020 <0.001
Ever on methadone No 0.85 (0.41-1.00) - - - - -
Currently 0.73 (0.27-0.85) -0.12 <0.001 -0.08 0.026  0.003
In past 0.73 (0.38-0.85) -0.12 <0.001 -0.05 0.026 0.080
Ever homeless No 0.80 (0.41-1.00) - - - - -
Yes, >6 mo ago 0.73 (0.29-0.85) -0.07 <0.001 -0.07 0.015 <0.001
Yes, in last 6 mo 0.66 (0.26-0.85) -0.14 <0.001 -0.12 0.029 <0.001
Ever imprisoned No 0.74 (0.38-0.88) - - - - -
Yes 0.71 (0.26-0.85) -0.04 0.088 -0.02 0.015 0.248
Health Board
of residence
Other 0.76 (0.41-0.88) - - - - -
GGC 0.66 (0.22-0.85) -0.10 <0.001 -0.08 0.018 <0.001
coefficient
GGC, Greater Glasgow & Clyde. Self-rated alcohol use categories were deﬁned as: high (>21 units/week for men; >14 for women); moderate (>0 to 21 units/week for men; >0
to 14 for women); and non-drinker (0 units/week).
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Second, our study population predominantly consists of
current injectors, and thus is clearly relevant for CE studies spe-
ciﬁcally addressing this group [30]. However, ex-PWID are
under-represented (they were only recruited if accessing harm
reduction services) and so sampling bias and generalisability to
ex-PWID needs to be considered.
Third, our study population consisted of PWID with a rela-
tively short injecting career (median 10 years); therefore (as
outlined above) we do not expect many to have developed
HCV-related complications within this relatively short duration
of living with chronic infection. However, those PWID who have
developed HCV-related disease are more likely to have been
tested and diagnosed (and so will be in the chronic HCV/aware
group); the difference in QoL we observed between chronic
HCV/aware and chronic HCV/unaware individuals needs to be
considered in light of this potential bias. Having said this, among
HCV antibody- and RNA-positive PWID who had been tested in
the past, QoL was still lower among those aware (0.66; Table 2)
compared with those unaware (0.74) of their infection.
Fourth, due to lack of data on social deprivation, we were
unable to control for socio-economic inequalities between HCV
status groups. Partial control was achieved by adjusting for
health board, a greater number of chronic HCV/aware and chronic
HCV/unaware respondents resided in GGC HB, which revealed
large independent effects for this covariate. Adjustment for
socio-economic variables may inﬂuence the QoL difference seen
between chronic HCV/aware and chronic HCV/unaware groups.
Finally, because of our cross-sectional study design, we cannot
make causal inferences regarding the relationship between
awareness of serostatus and QoL. More research is required, ide-
ally comparing QoL elicited before and after diagnosis with HCV,
to clarify this issue.
For PWID chronically infected with HCV, being aware of their
infected status was associated with a reduced health-related QoL;
there was no evidence for any QoL reduction solely attributable
to the presence of infection in undiagnosed PWID, when age (a
proxy for duration of infection) and other covariates are con-
trolled for. These ﬁndings provide useful data on the change in
QoL post-diagnosis. Additional research is required to ascertain
the relative contributions of the duration of HCV infection (par-
ticularly in infected ex-PWID, who will have been infected for a
longer time) and awareness of one’s infected status to QoL.
On the basis of the maxim that an intervention should do
more good than harm, our ﬁnding that awareness of infection
status among chronically HCV-infected current PWID is associ-
ated with a reduction in QoL implies that unless clinicians are
prepared, and have the means, to act on a HCV diagnosis, the case
for promoting the identiﬁcation of infected individuals is weak.
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